2invest AG
SYGNIS AG presents innovative technologies in molecular biology at two renowned scientific conferences
DGAP-News: SYGNIS AG / Key word(s): Conference Press Release SYGNIS AG presents innovative technologies in molecular biology at two renowned scientific conferences Madrid, Spain, and Heidelberg, Germany, October 04, 2016 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that the Company has presented its revolutionary TruePrime(TM) technology at two renowned scientific conferences. From September 14th – 16th, the SINGLE CELL GENOMICS MEETING was held in Cambridge, United Kingdom. Single cell genomics is a revolutionary technology transforming many fields of biological research, including immunology and cancer. Today, many different applications (e.g. single cell genome sequencing, single cell transcriptomics, and various single cell epigenetic profiling approaches) are being used by researchers to characterize the genetic and functional properties of individual cells under native conditions, leading to numerous experimental and clinical opportunities. During the meeting, cutting edge topics and questions were raised. Questions discussed included: “Which technologies are going to set the standard in the field?”, “How can single cell genomics and epigenomics technologies be integrated in workflows?” or “What are the immediate implications for immunology, cancer research and germ cells?”. For SYGNIS, this conference was one of the key events to promote its technology in the single cell market, one of the most important markets for the Company. SYGNIS’ TruePrime(TM) products provide superior advantages over current technologies and solve most of the problems that researchers are facing in single cell analysis today. SYGNIS introduced and promoted its TruePrime(TM) technology as key new technology for DNA amplification to the scientific community in a poster presentation. “It is part of our strategy to present our innovative TruePrime technology at all high level meetings, with the goal of becoming the new gold standard for Whole Genome Amplification, targeting Next Generation Sequencing users, and consequently the NGS market”, commented Pilar de la Huerta, Co-CEO and CFO of SYGNIS AG. “As a result of our marketing activities, we receive a lot of positive feedback from the scientific community. This makes us very confident that we can accelerate our sales as these types of tools are a key element for researchers, moreover the NGS market is growing at a double digit rate.” SYGNIS AG also presented at the AGBT (Advances in Genome Biology and Technology) PRECISON HEALTH MEETING. The conference took place in Arizona, USA, from September 22nd – 24th. Since 2000, the AGBT meeting has been recognized worldwide among researchers as the preeminent conference where scientists and experts in the fields of genomics and biology meet to collaborate, advance research, educate and explore new opportunities. This meeting aims to enable contact among pioneering researchers and developers of genome technologies to first movers in healthcare who are establishing cutting edge standard of care applications of genome technology in every day clinical practice. At this event, SYGNIS presented and promoted its TruePrime(TM) technology as key new technology for DNA amplification to the scientific community in a poster presentation. For further information, please contact:
About SYGNIS AG: www.sygnis.com SYGNIS AG is specialized in the development and the commercialization of proprietary technologies and offers a wide range of different commercial products addressing key challenges in molecular biology. With the acquisition of Expedeon Holdings, Ltd. based in Cambridge, UK, SYGNIS has added a complementary proteomic product portfolio. Resulting from this significant expansion, SYGNIS’ product portfolio now covers the entire workflow of molecular biology. The products are sold through a direct sales force and several distribution partners in Europe, the US and Asia. SYGNIS AG has offices in Germany, Spain and the UK, production sites in the UK and the US as well as sales offices in Asia. The company is listed on the German Stock Exchange in Frankfurt in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03). ### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###
2016-10-04 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English | |
Company: | SYGNIS AG | |
Waldhofer Str. 104 | ||
69123 Heidelberg | ||
Germany | ||
Phone: | +49 (0) 6221 3540 125 | |
Fax: | +49 (0) 6221 3540 127 | |
E-mail: | investors@sygnis.com | |
Internet: | www.sygnis.com | |
ISIN: | DE000A1RFM03 | |
WKN: | A1RFM0 | |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange | |
End of News | DGAP News Service |